TAFRO syndrome: A disease that known is half cured

Thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome is rare in clinical practice. It is a systemic inflammatory disease caused by a cytokine storm. Its clinical manifestations include thrombocytopenia, systemic edema, fever, bone marrow fibrosis, renal insufficiency, and organ enlargement. The high mortality rate of TAFRO syndrome is due to the difficulty of acquiring biopsy samples for diagnosis and the rapid disease progression. This disease is poorly understood by clinicians. Early detection, accurate diagnosis, and timely treatment play key roles in prolonging the survival of the patients. This review summarizes the latest progress in the pathogenesis, diagnostic criteria, and treatment regimens of TAFRO syndrome, aiming to help clinicians better understand TAFRO syndrome and improve its diagnosis and treatment.

[1]  Xiao-Liu Shi,et al.  TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report , 2022, Hematological oncology.

[2]  M. Murakami,et al.  Glycogen synthase kinase 3β/CCR6‐positive bone marrow cells correlate with disease activity in multicentric Castleman disease‐TAFRO , 2021, British journal of haematology.

[3]  K. Tsuruya,et al.  Renal histological continuum of TAFRO syndrome: A case report and literature review. , 2021, Clinical nephrology.

[4]  K. Asai,et al.  Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit , 2021, Journal of medical cases.

[5]  Xiaoying Hu,et al.  The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.

[6]  S. Pierson,et al.  Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO , 2021, Journal of cellular and molecular medicine.

[7]  N. Jadhav,et al.  TAFRO syndrome: A case report with biopsy findings from three sites , 2021, American Journal of Clinical Pathology.

[8]  É. Oksenhendler,et al.  Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort , 2021, British Journal of Haematology.

[9]  K. Abe,et al.  TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report , 2021, Clinical Journal of Gastroenterology.

[10]  S. Murata,et al.  Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab , 2021, Medicina.

[11]  T. Nakatani,et al.  Fatal case of TAFRO syndrome with unilateral adrenal hemorrhage in early-stage disease , 2021, Journal of clinical and experimental hematopathology : JCEH.

[12]  R. Sumiyoshi,et al.  POS1353 SERUM PROTEOMICS REVEALS INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS-1 AS BIOMARKERS FOR IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE , 2021 .

[13]  T. Origuchi,et al.  Patient’s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome , 2021, International Journal of Hematology.

[14]  S. Pillai,et al.  Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. , 2021, European journal of internal medicine.

[15]  N. Tsuboi,et al.  TAFRO Syndrome With Kidney Involvement: A Case Series of Patients With Kidney Biopsies , 2021, Kidney medicine.

[16]  É. Oksenhendler,et al.  JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report , 2021, Annals of Internal Medicine.

[17]  D. Fajgenbaum,et al.  UCD with MCD-like inflammatory state: surgical excision is highly effective. , 2021, Blood advances.

[18]  A. Takamura,et al.  A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report , 2021, Journal of Medical Case Reports.

[19]  N. Kadowaki,et al.  Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab , 2021, Modern rheumatology case reports.

[20]  S. Tamiya,et al.  A Case of Repeated TAFRO Syndrome-Like Symptoms and Retroperitoneal Hemorrhage in a Patient With Sjögren Syndrome , 2020, Cureus.

[21]  Ji-hong Zhu,et al.  Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature , 2020, BMC Nephrology.

[22]  M. Nogier,et al.  [TAFRO syndrome and cutaneous necrotizing vasculitis]. , 2020, La Revue de medecine interne.

[23]  Noritaka Yada,et al.  Complete Resolution of a Case of TAFRO Syndrome Accompanied by Mediastinal Panniculitis, Adrenal Lesion, and Liver Damage with Hyperbilirubinemia , 2020, Internal medicine.

[24]  S. Singh,et al.  In silico insights on IL-6: A Potential target for Multicentric Castleman Disease. , 2020, Current computer-aided drug design.

[25]  L. Powell,et al.  Primarily VEGF-Driven Etiopathogenesis of Tafro Syndrome and Fibroblastic Reticular Cells As a Probable Castleman Cell - Qualitative Metasynthesis , 2020 .

[26]  K. Kagawa,et al.  An Autopsy Case of TAFRO Syndrome with Type II Respiratory Failure , 2020, The American journal of case reports.

[27]  N. Kurose,et al.  Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan , 2020, International Journal of Hematology.

[28]  T. Takeuchi,et al.  Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review , 2020, Annals of Hematology.

[29]  K. Migita,et al.  Primary Sjögren's Syndrome Accompanied by Clinical Features of TAFRO Syndrome , 2020, Case reports in rheumatology.

[30]  Shogo Minamikawa,et al.  A pediatric case of tocilizumab‐resistant TAFRO syndrome treated successfully with rituximab , 2020, Pediatric blood & cancer.

[31]  P. Zinzani,et al.  Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report , 2020, European journal of haematology.

[32]  V. Vasilyev,et al.  [Idiopathic multicentric Castleman's disease]. , 2020, Terapevticheskii arkhiv.

[33]  Yan Qin,et al.  Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide , 2020, Kidney and Blood Pressure Research.

[34]  F. Vandergheynst,et al.  Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology , 2020, BMJ Case Reports.

[35]  K. Ohashi,et al.  The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome , 2020, Kidney international reports.

[36]  J. Colgan.  mTOR signaling as a driver of Castleman disease. , 2020, Blood.

[37]  M. Betts,et al.  Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. , 2020, JCI insight.

[38]  M. Mori,et al.  Liver cirrhosis in a child associated with Castleman's disease: A case report. , 2020, World journal of clinical cases.

[39]  A. Hot,et al.  Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients , 2020, The American journal of case reports.

[40]  H. Zhang,et al.  [A report of six TAFRO syndrome: clinical characteristics, diagnosis and treatment analysis]. , 2020, Zhonghua yi xue za zhi.

[41]  A. Dispenzieri,et al.  Overview of Castleman Disease. , 2020, Blood.

[42]  Alexander V Penson,et al.  Genetic basis for iMCD-TAFRO , 2020, Oncogene.

[43]  T. Hirano,et al.  Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review , 2020, Modern rheumatology case reports.

[44]  Jie Jin,et al.  Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study , 2020, Journal of Cancer Research and Clinical Oncology.

[45]  Y. Ishigaki,et al.  2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome , 2019, International Journal of Hematology.

[46]  R. Suzuki,et al.  Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan , 2019, Journal of clinical and experimental hematopathology : JCEH.

[47]  M. Kawamoto,et al.  TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review , 2019, BMC Nephrology.

[48]  N. Kurose,et al.  The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. , 2019, Pathology, research and practice.

[49]  K. Tsuneyama,et al.  Hepatic Campylobacter jejuni infection in patients with Castleman‐Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome) , 2019, Pathology international.

[50]  S. Pierson,et al.  Increased mTOR activation in idiopathic multicentric Castleman disease , 2019, Clinical Lymphoma Myeloma and Leukemia.

[51]  G. Wertheim,et al.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. , 2019, The Journal of clinical investigation.

[52]  A. Rezaei,et al.  TAFRO syndrome with skin manifestations treated with bortezomib and tocilizumab; a case report , 2019, Immunopathologia Persa.

[53]  Jingyu Chen,et al.  Upstream regulators of phosphoinositide 3‐kinase and their role in diseases , 2019, Journal of cellular physiology.

[54]  J. Kuroda,et al.  Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? , 2019, American journal of hematology.

[55]  N. Ban,et al.  Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature , 2019, Nagoya journal of medical science.

[56]  N. R. Patel,et al.  TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient , 2019, Cureus.

[57]  M. Satoh,et al.  Pathological findings of progressive renal involvement in a patient with TAFRO syndrome , 2019, CEN Case Reports.

[58]  S. Fujiwara,et al.  TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report , 2019, Acta Haematologica.

[59]  H. Wada,et al.  Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab , 2019, International Journal of Hematology.

[60]  Y. Sekiguchi,et al.  A case of TAFRO syndrome, a variant of multicentric Castleman’s disease, successfully treated with corticosteroid and cyclosporine A , 2019, Modern rheumatology.

[61]  J. Rossi,et al.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. , 2018, Blood.

[62]  A. Takamura,et al.  The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report , 2018, Journal of Medical Case Reports.

[63]  S. Bozkurt,et al.  TAFRO Syndrome: A Case Report from Turkey and Review of the Literature , 2018, International journal of hematology-oncology and stem cell research.

[64]  A. Stonestrom,et al.  Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease , 2018, American journal of hematology.

[65]  A. Kato,et al.  Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage , 2018, Clinical nephrology. Case studies.

[66]  A. Morinobu,et al.  Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review , 2018, Medicine.

[67]  K. Notohara,et al.  TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review , 2018, Modern rheumatology.

[68]  K. Ohashi,et al.  Renal histology in a patient with TAFRO syndrome: a case report. , 2018, Human pathology.

[69]  A. Yoneyama,et al.  Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with Trichosporon asahii infection in the lungs and myocardial infarction: an autopsy case report and literature review , 2018, Renal Replacement Therapy.

[70]  R. Warnke,et al.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. , 2018, Blood advances.

[71]  Hiroki Sato,et al.  Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome , 2018, Lupus.

[72]  K. Ohashi,et al.  TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report , 2018, CEN Case Reports.

[73]  K. Yoshizaki,et al.  The Role of Interleukin-6 in Castleman Disease. , 2018, Hematology/oncology clinics of North America.

[74]  F. Kondo,et al.  Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome , 2018, Internal medicine.

[75]  A. Yokoyama,et al.  TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin , 2017, Internal medicine.

[76]  E. Jaffe,et al.  TAFRO syndrome: A case report and review of the literature. , 2017, Human pathology.

[77]  K. Kagawa,et al.  Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure , 2017, Internal medicine.

[78]  D. Fajgenbaum,et al.  TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature , 2017, Front. Med..

[79]  S. Okamoto,et al.  Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide , 2017, Internal medicine.

[80]  I. Marijanović,et al.  TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. , 2017, Bosnian journal of basic medical sciences.

[81]  N. Takahashi,et al.  Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging , 2017, Internal medicine.

[82]  Min Yang,et al.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases , 2017, Frontiers of Medicine.

[83]  K. Young,et al.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. , 2017, Blood.

[84]  J. Rossi,et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. , 2017, Blood.

[85]  R. Ando,et al.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome , 2017, CEN Case Reports.

[86]  N. Hamerschlak,et al.  A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids , 2017, Medicine.

[87]  T. Yoshino,et al.  Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome , 2017, Scientific Reports.

[88]  Yuquan Wei,et al.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway* , 2016, The Journal of Biological Chemistry.

[89]  T. Sekine,et al.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome , 2016, Internal medicine.

[90]  J. Butera,et al.  TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature , 2016, Case reports in hematology.

[91]  Y. Inagaki,et al.  An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy , 2016, Respirology case reports.

[92]  O. Miura,et al.  Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy , 2016, International Journal of Hematology.

[93]  Dao-bin Zhou,et al.  Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman’s disease: renal function is an important prognostic factor , 2016, Scientific Reports.

[94]  M. Kojima,et al.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version , 2016, International Journal of Hematology.

[95]  Y. Okuno,et al.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids , 2016, International Journal of Hematology.

[96]  T. Yoshino,et al.  Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease , 2016, American journal of hematology.

[97]  Z. Estrov,et al.  Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome , 2015, American journal of hematology.

[98]  R. Kurzrock,et al.  A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease , 2015, Oncotarget.

[99]  M. Tsudo,et al.  Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2. , 2015, The Tohoku journal of experimental medicine.

[100]  M. Taniwaki,et al.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome , 2015, Clinical case reports.

[101]  N. Munshi,et al.  Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab , 2015, The Patient - Patient-Centered Outcomes Research.

[102]  R. Pazdur,et al.  FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease , 2015, Clinical Cancer Research.

[103]  J. Rossi,et al.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Oncology.

[104]  M. Kojima,et al.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012 , 2013, Journal of clinical and experimental hematopathology : JCEH.

[105]  Jayson A. Neil,et al.  Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. , 2013, Advances in biological regulation.

[106]  Jie Jin,et al.  High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease , 2012, Annals of Hematology.

[107]  J. Molitor,et al.  Castleman disease and associated autoimmune disease , 2012, Current opinion in rheumatology.

[108]  R. Kurzrock,et al.  Castleman's disease: from basic mechanisms to molecular therapeutics. , 2011, The oncologist.

[109]  H. Shibuya,et al.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. , 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[110]  M. Kojima,et al.  Clinical Implications of Idiopathic Multicentric Castleman Disease Among Japanese: A Report of 28 Cases , 2008, International journal of surgical pathology.

[111]  Z. Estrov,et al.  The JAK-STAT pathway: a therapeutic target in hematological malignancies. , 2006, Current cancer drug targets.

[112]  R. Marasca,et al.  Lymphotropic herpes virus (EBV, HHV-6, HHV-8) DNA sequences in HIV negative Castleman's disease , 1996, Clinical molecular pathology.

[113]  B. Castleman,et al.  Case records of the Massachusetts General Hospital: Case No. 40231. , 1954, The New England journal of medicine.

[114]  R. Bridges,et al.  VERSION , 1922, Greece and Rome.

[115]  É. Oksenhendler,et al.  Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease , 2021 .

[116]  Yasuharu Sato,et al.  TAFRO Syndrome. , 2018, Hematology/oncology clinics of North America.

[117]  N. Yamakita,et al.  Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome. , 2016, Internal medicine.

[118]  Toshiaki Hayashi,et al.  TAFRO syndrome showing cholangitis on liver biopsy. , 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[119]  K. Ohmura,et al.  Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. , 2016, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[120]  M. Kojima,et al.  Proposed diagnostic criteria, disease severity classification, and treatment strategy for a novel disorder; TAFRO syndrome. , 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[121]  A. Dispenzieri.  Castleman disease. , 2008, Cancer treatment and research.

[122]  M. Alper,et al.  Journal of Experimental & Clinical Assisted Reproduction Molecular Mechanisms in Uterine Epithelium during Trophoblast Binding: the Role of Small Gtpase Rhoa in Human Uterine Ishikawa Cells , 2005 .

[123]  嶋田 光恵.  IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators , 2002 .